CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer

British Journal of Cancer

Volumn 115, Issue 5, 2016, Pages 553-563

  Bronger, Holger ^a   Singer, Judith ^a   Windmüller, Claudia ^a   Reuning, Ute ^a   Zech, Daniela ^a   Delbridge, Claire ^b   Dorn, Julia ^a   Kiechle, Marion ^a   Schmalfeldt, Barbara ^a,c   Schmitt, Manfred ^a   Avril, Stefanie ^b,d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

CXCL9; CXCL10; ovarian cancer; cyclooxygenase; tumour infiltrating lymphocytes

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; ANTINEOPLASTIC AGENT; CD3 ANTIGEN; CD56 ANTIGEN; CELECOXIB; CXCL9 CHEMOKINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; PROSTAGLANDIN E2; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; LIGAND; PROSTAGLANDIN SYNTHASE INHIBITOR;

ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOREDUCTIVE SURGERY; DOSE RESPONSE; DRUG MEGADOSE; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; GENE OVEREXPRESSION; HIGH GRADE SEROUS OVARIAN CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; OVARIAN CANCER CELL LINE; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION; METABOLISM; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR CELL LINE;

CELL LINE, TUMOR; CHEMOKINE CXCL10; CHEMOKINE CXCL9; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; INDOMETHACIN; LIGANDS; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84982920531     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.172     Document Type: Article

References (51)

1. Abastado JP. (2012). The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor. Cancer Res 72: 2159-2161
2. Bellati F, Napoletano C, Gasparri ML, Ruscito I, Marchetti C, Pignata S, Tomao F, Benedetti Panici P, Nuti M. (2012). Current knowledge and open issues regarding bevacizumab in gynaecological neoplasms. Crit Rev Oncol Hematol 83: 35-46
3. Bellati F, Napoletano C, Ruscito I, Visconti V, Antonilli M, Gasparri ML, Zizzari IG, Rahimi H, Palaia I, Rughetti A, Benedetti Panici P, Nuti M. (2013). Past, present and future strategies of immunotherapy in gynecological malignancies. Curr Mol Med 13: 648-669
4. Bronger H, Konig J, Kopplow K, Steiner HH, Ahmadi R, Herold-Mende C, Keppler D, Nies AT. (2005). ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. Cancer Res 65: 11419-11428
5. Bronger H, Kraeft S, Schwarz-Boeger U, Cerny C, Stöckel A, Avril S, Kiechle M, Schmitt M. (2012). Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer. Breast Cancer Res 14: R30
6. Chen DS, Mellman I. (2013). Oncology meets immunology: the cancerimmunity cycle. Immunity 39: 1-10
7. Clarke B, Tinker AV, Lee CH, Subramanian S, van de Rijn M, Turbin D, Kalloger S, Han G, Ceballos K, Cadungog MG, Huntsman DG, Coukos G, Gilks CB. (2009). Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol 22: 393-402
8. Clarke DL, Clifford RL, Jindarat S, Proud D, Pang L, Belvisi M, Knox AJ. (2010). TNFalpha and IFNgamma synergistically enhance transcriptional activation of CXCL10 in human airway smooth muscle cells via STAT-1, NF-kappa B, and the transcriptional coactivator CREB-binding protein. J Biol Chem 285: 29101-29110
9. Daikoku T, Wang D, Tranguch S, Morrow JD, Orsulic S, DuBois RN, Dey SK. (2005). Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res 65: 3735-3744
10. Dannenberg AJ, Subbaramaiah K. (2003). Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 4: 431-436
11. Denkert C, Kobel M, Pest S, Koch I, Berger S, Schwabe M, Siegert A, Reles A, Klosterhalfen B, Hauptmann S. (2002). Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 160: 893-903
12. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, von Torne C, Weichert W, Engels K, Solbach C, Schrader I, Dietel M, von Minckwitz G. (2010). Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28: 105-113
13. Furuya M, Suyama T, Usui H, Kasuya Y, Nishiyama M, Tanaka N, Ishiwata I, Nagai Y, Shozu M, Kimura S. (2007). Up-regulation of CXC chemokines and their receptors: implications for proinflammatory microenvironments of ovarian carcinomas and endometriosis. Hum Pathol 38: 1676-1687
14. Gasparri ML, Attar R, Palaia I, Perniola G, Marchetti C, Di Donato V, Farooqi AA, Papadia A, Panici PB. (2015). Tumor infiltrating lymphocytes in ovarian cancer. Asian Pac J Cancer Prev 16: 3635-3638
15. Gasparri ML, Bellati F, Napoletano C, Panici PB, Nuti M. (2013). Interaction between Treg cells and angiogenesis: a dark double track. Int J Cancer 132: 2469
16. Gorbachev AV, Kobayashi H, Kudo D, Tannenbaum CS, Finke JH, Shu S, Farber JM, Fairchild RL. (2007). CXC chemokine ligand 9/monokine induced by IFN-gamma production by tumor cells is critical for T cellmediated suppression of cutaneous tumors. J Immunol 178: 2278-2286
17. Gupta RA, Tejada LV, Tong BJ, Das SK, Morrow JD, Dey SK, DuBois RN. (2003). Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res 63: 906-911
18. Haas AR, Sun J, Vachani A, Wallace AF, Silverberg M, Kapoor V, Albelda SM. (2006). Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin Cancer Res 12: 214-222
19. Hsin LJ, Kao HK, Chen IH, Tsang NM, Hsu CL, Liu SC, Chang YS, Chang KP. (2013). Serum CXCL9 levels are associated with tumor progression and treatment outcome in patients with nasopharyngeal carcinoma. PLoS One 8: e80052
20. Kandalaft LE, Powell Jr. DJ, Singh N, Coukos G. (2011). Immunotherapy for ovarian cancer: what's next? J Clin Oncol 29: 925-933
21. Kohrt HE, Houot R, Marabelle A, Cho HJ, Osman K, Goldstein M, Levy R, Brody J. (2012). Combination strategies to enhance antitumor ADCC. Immunotherapy 4: 511-527
22. Kondo T, Ito F, Nakazawa H, Horita S, Osaka Y, Toma H. (2004). High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma. J Urol 171: 2171-2175
23. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, Chang A, Coukos G, Liu R, Zou W. (2009). Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114: 1141-1149
24. Kundu N, Fulton AM. (2002). Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res 62: 2343-2346
25. Kundu N, Walser TC, Ma X, Fulton AM. (2005). Cyclooxygenase inhibitors modulate NK activities that control metastatic disease. Cancer Immunol Immunother 54: 981-987
26. Leone Roberti Maggiore U, Bellati F, Ruscito I, Gasparri ML, Alessandri F, Venturini PL, Ferrero S. (2013). Monoclonal antibodies therapies for ovarian cancer. Expert Opin Biol Ther 13: 739-764
27. Liu M, Matsumura N, Mandai M, Li K, Yagi H, Baba T, Suzuki A, Hamanishi J, Fukuhara K, Konishi I. (2009). Classification using hierarchical clustering of tumor-infiltrating immune cells identifies poor prognostic ovarian cancers with high levels of COX expression. Mod Pathol 22: 373-384
28. Lunardi S, Jamieson NB, Lim SY, Griffiths KL, Carvalho-Gaspar M, Al-Assar O, Yameen S, Carter RC, McKay CJ, Spoletini G, D'Ugo S, Silva MA, Sansom OJ, Janssen KP, Muschel RJ, Brunner TB. (2014). IP-10/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes recruitment and correlates with poor survival. Oncotarget 5: 11064-11080
29. Mariya T, Hirohashi Y, Torigoe T, Asano T, Kuroda T, Yasuda K, Mizuuchi M, Sonoda T, Saito T, Sato N. (2014). Prognostic impact of human leukocyte antigen class I expression and association of platinum resistance with immunologic profiles in epithelial ovarian cancer. Cancer Immunol Res 2: 1220-1229
30. Markosyan N, Chen EP, Evans RA, Ndong V, Vonderheide RH, Smyth EM. (2013). Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity. Breast Cancer Res 15: R75
31. Möbus V, Gerharz CD, Press U, Moll R, Beck T, Mellin W, Pollow K, Knapstein PG, Kreienberg R. (1992). Morphological, immunohistochemical and biochemical characterization of 6 newly established human ovarian carcinoma cell lines. Int J Cancer 52: 76-84
32. Müller MA, Opfer J, Brunie L, Volkhardt LA, Sinner EK, Boettiger D, Bochen A, Kessler H, Gottschalk KE, Reuning U. (2013). The glycophorin A transmembrane sequence within integrin alphavbeta3 creates a nonsignaling integrin with low basal affinity that is strongly adhesive under force. J Mol Biol425 2988-3006
33. Muthuswamy R, Berk E, Junecko BF, Zeh HJ, Zureikat AH, Normolle D, Luong TM, Reinhart TA, Bartlett DL, Kalinski P. (2012). NF-kappaB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res 72: 3735-3743
34. Rabinowich H, Suminami Y, Reichert TE, Crowley-Nowick P, Bell M, Edwards R, Whiteside TL. (1996). Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. Int J Cancer 68: 276-284
35. Rainczuk A, Rao JR, Gathercole JL, Fairweather NJ, Chu S, Masadah R, Jobling TW, Deb-Choudhury S, Dyer J, Stephens AN. (2014). Evidence for the antagonistic form of CXC-motif chemokine CXCL10 in serous epithelial ovarian tumours. Int J Cancer 134: 530-541
36. Redjimi N, Raffin C, Raimbaud I, Pignon P, Matsuzaki J, Odunsi K, Valmori D, Ayyoub M. (2012). CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity. Cancer Res 72: 4351-4360
37. Reyners AK, de Munck L, Erdkamp FL, Smit WM, Hoekman K, Lalisang RI, de Graaf H, Wymenga AN, Polee M, Hollema H, van Vugt MA, Schaapveld M, Willemse PH. (2012). A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study. Ann Oncol 23: 2896-2902
38. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K. (2005). Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102: 18538-18543
39. Schmalfeldt B, Kuhn W, Reuning U, Pache L, Dettmar P, Schmitt M, Janicke F, Hofler H, Graeff H. (1995). Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res 55: 3958-3963
40. Sharma S, Zhu L, Yang SC, Zhang L, Lin J, Hillinger S, Gardner B, Reckamp K, Strieter RM, Huang M, Batra RK, Dubinett SM. (2005). Cyclooxygenase 2 inhibition promotes IFN-gamma-dependent enhancement of antitumor responses. J Immunol 175: 813-819
41. Shuptrine CW, Surana R, Weiner LM. (2012). Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol 22: 3-13
42. Specht K, Harbeck N, Smida J, Annecke K, Reich U, Nährig J, Langer R, Mages J, Busch R, Kruse E, Klein-Hitpass L, Schmitt M, Kiechle M, Höfler H. (2009). Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy. Breast Cancer Res Treat 118: 45-56
43. Suyama T, Furuya M, Nishiyama M, Kasuya Y, Kimura S, Ichikawa T, Ueda T, Nikaido T, Ito H, Ishikura H. (2005). Up-regulation of the interferon gamma (IFN-gamma)-inducible chemokines IFN-inducible T-cell alpha chemoattractant and monokine induced by IFN-gamma and of their receptor CXC receptor 3 in human renal cell carcinoma. Cancer 103: 258-267
44. Takeyama H, Wakamiya N, O'Hara C, Arthur K, Niloff J, Kufe D, Sakarai K, Spriggs D. (1991). Tumor necrosis factor expression by human ovarian carcinoma in vivo. Cancer Res 51: 4476-4480
45. The Cancer Genome Atlas Research Network. (2011). Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615
46. Tomsova M, Melichar B, Sedlakova I, Steiner I. (2008). Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol 108: 415-420
47. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro B, Traficante N, Fereday S, Hung JA, Chiew YE, Haviv I, Gertig D, DeFazio A, Bowtell DD. (2008). Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14: 5198-5208
48. Tymoszuk P, Charoentong P, Hackl H, Spilka R, Muller-Holzner E, Trajanoski Z, Obrist P, Revillion F, Peyrat JP, Fiegl H, Doppler W. (2014). High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer. BMC Cancer 14: 257
49. Wendel M, Galani IE, Suri-Payer E, Cerwenka A. (2008). Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res 68: 8437-8445
50. Yang X, Chu Y, Wang Y, Zhang R, Xiong S. (2006). Targeted in vivo expression of IFN-gamma-inducible protein 10 induces specific antitumor activity. J Leukoc Biol 80: 1434-1444
51. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G. (2003). Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 203-213